Citigroup Maintains Neutral on Ovid Therapeutics, Raises Price Target to $2.5
Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and raises the price target from $2.4 to $2.5.
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
All news is property of their respective owners.
